Draft resolution on AMR prepared for next WHA

Draft resolution on AMR prepared for next WHA

  • 03/02/2019

The executive board of the WHO’s World Health Assembly has agreed on a draft solution on Antimicrobial Resistance. Sustainable innovation financing is among the topics addressed.

On its 114th session, the executive board of the World Heath Organization’s World Health Assembly has finalized a draft resolution covering all recommendations, invitations and requests with regard to activities on the political level that help to combat antimicrobial resistance globally.  

The draft resolution was proposed by Argentina, Australia, Canada, Chile, China, Israel, Kenya, Oman, Panama, Russian Federation, South Africa, Sri Lanka, Switzerland, United States of America, and Member States of the European Union. It will be presented during the 72nd World Health Assembly in May 2019.

Among the recommendations made,

  • PP6 recognizes “the pressing need for investing in high-quality research and development, including basic research for antimicrobials, diagnostic technologies, vaccines and alternative preventive measures across sectors.” In addition, it calls for “ensuring adequate access to those in need of quality, safe, efficacious and affordable existing and new antimicrobials, diagnostic technologies and vaccines, while promoting effective stewardship.
  • Furthermore, PP12 reaffirms “the global commitment to combat AMR with continued, high-level, political efforts as a coordinated international community, emphasizing the critical need to accelerate Member States’ development, and implementation of their national action plans (NAPs) with a One Health approach.
  • The draft resolution also welcomes “the new tripartite agreement on AMR, and encourages the Tripartite Agencies (FAO, OIE and WHO) and UNEP to establish a clear coordination for its implementation and to align reporting to their governing bodies on progress under the joint work plan according to their respective mandates.”

In the document, among others, the WHO member states are also urged to

  • remain committed at the highest political level to combating AMR, using a One Health approach, and to reducing the burden of disease, mortality, and disability associated with it;
  • increase efforts to implement the actions and the strategic objectives of the AMR GAP, and take steps to address emerging issues;”
  • “enhance cooperation at all levels for concrete action towards combatting AMR, including through health systems strengthening, capacity building, and research and regulatory capacity and technical assistance, including, where appropriate, through twinning programs that build on best practices, emerging evidence and innovation.

In the draft, cooperation between all stakeholders is given a high priority. International, regional and national partners, and other relevant stakeholders, are invited to

  • “coordinate efforts in order to avoid duplication and gaps and leverage resources more effectively;”
  • increase efforts and enhance multistakeholder collaboration to develop and apply tools to address AMR following a One Health approach, including through coordinated, responsible, sustainable and innovative approaches to R&D, including but not limited to quality, safe, efficacious and affordable antimicrobials, and alternative medicines and therapies, vaccines and diagnostic tools, WASH, including infection prevention and control measures;
  • consider AMR priorities in funding and programmatic decisions, including innovative ways to mainstream AMR relevant activities in existing international development financing”

Finally, the draft resolution also formulates several tasks which focus on a sustainable way of innovation funding and financing. Among others, the Director-General is requested to 

  • support member states to mobilize adequate predictable and sustained funding and human and financial resources and investment through national, bilateral and multilateral channels to support the development and implementation of national action plans, research and development on existing and new antimicrobial medicines, diagnostics, and vaccines, and other technologies and strengthening of related infrastructure including through engagement with multilateral development banks and traditional and voluntary innovative financing and investment mechanisms based on priorities and local needs set by governments and on ensuring public return on investment
  • collaborate with the World Bank and other financial institutions, OECD, and regional economic communities, to continue to make and apply the economic case for sustainable investment in AMR.” 

The 72nd Session of the WHO’s World Health Assembly (WHA) will take place in Geneva, Switzerland, from 20-28 May 2019. The WHA is the decision-making body of WHO. It is attended by delegations from all WHO Member States and focuses on a specific health agenda prepared by the Executive Board. The main functions of the WHA are to determine the policies of the Organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget.